IBIO earnings: next report 2026-09-04, real EPS beat/miss history, analyst consensus Buy, P/E -2.40. Updated 2026-07-23.
iBio (IBIO) Research Hub
iBio (IBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.205 USD (-4.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.40, market cap 0.02B. This hub links to the full technical, earnings and options research available for IBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.205 USD (-4.37%) |
| 52-week range | 1.2 USD – 1.77 USD |
| Trend regime | Range |
| 14-day RSI | 35 (Bearish) |
| Trailing P/E | -2.40 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-04 |
Available research for IBIO
Covered Call on IBIO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IBIO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IBIO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
IBIO technical analysis: range, last 1.205 USD, RSI 35, 52w range 1.2 USD–1.77 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IBIO in?
iBio (IBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IBIO in an uptrend or downtrend?
As of 2026-09-11, IBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IBIO's trailing P/E ratio?
IBIO's trailing P/E is -2.40, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does IBIO next report earnings?
IBIO is next scheduled to report earnings on 2026-09-04, with a consensus EPS estimate of -0.07 USD.